Ergocalciferol Capsules, 1.25 mg/1
Ergocalciferol Capsules, · CAPSULE · Preferred Pharmaceuticals Inc.
Ergocalciferol Capsules, is a capsule containing ergocalciferol capsules, at 1.25 mg/1, taken oral. Manufactured by Preferred Pharmaceuticals Inc..
Key Facts
- Brand Name
- Ergocalciferol Capsules,
- Generic Name
- Ergocalciferol Capsules,
- NDC Code (Product)
68788-4042- Manufacturer
- Preferred Pharmaceuticals Inc.
- Strength
- 1.25 mg/1
- Dosage Form
- CAPSULE
- Route
- ORAL
- Marketing Status
- Application #
- ANDA204276
- Drug Class
- Provitamin D2 Compound [EPC]
- Marketing Start
- 10/17/2025
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Full Prescribing Information
Indications & Usage
INDICATIONS AND USAGE Ergocalciferol Capsules are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia.
Dosage & Administration
DOSAGE AND ADMINISTRATION THE RANGE BETWEEN THERAPEUTIC AND TOXIC DOSES IS NARROW. Vitamin D Resistant Rickets : 12,000 to 500,000 IU units daily. Hypoparathyroidism: 50,000 to 200,000 IU units daily concomitantly with calcium lactate 4 g, six times per day. DOSAGE MUST BE INDIVIDUALIZED UNDER CLOSE MEDICAL SUPERVISION. Calcium intake should be adequate. Blood calcium and phosphorus determinations must be made every 2 weeks or more frequently if necessary. X-rays of the bones should be taken every month until condition is corrected and stabilized.
Warnings
WARNINGS Hypersensitivity to vitamin D may be one etiologic factor in infants with idiopathic hypercalcemia. In these cases vitamin D must be strictly restricted. Keep out of the reach of children.
Contraindications
CONTRAINDICATIONS Ergocalciferol Capsules are contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of vitamin D, and hypervitaminosis D.
Drug Interactions
Drug Interactions Mineral oil interferes with the absorption of fat-soluble vitamins,including vitamin D preparations. Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with Ergocalciferol Capsules may cause hypercalcemia.
Adverse Reactions
ADVERSE REACTIONS Hypervitaminosis D is characterized by effects on the following organ system: Renal: Impairment of renal function with polyuria, nocturia, polydipsia, hypercalciuria, reversible azotemia, hypertension, nephrocalcinosis, generalized vascular calcification, or irreversible renal insufficiency which may result in death. CNS: Mental retardation. Soft Tissues: Widespread calcification of the soft tissues, including the heart, blood vessels, renal tubules, and lungs. Skeletal: Bone demineralization (osteoporosis) in adults occurs concomitantly. Decline in the average rate of linear growth and increased mineralization of bones in infants and children (dwarfism) vague aches, stiffness, and weakness. Gastrointestinal: Nausea, anorexia, constipation. Metabolic: Mild acidosis, anemia, weight loss.
Frequently Asked Questions
What is Ergocalciferol Capsules, used for?
Ergocalciferol Capsules, contains Ergocalciferol Capsules,. It is a capsule taken oral. Consult your doctor for specific uses.
Is Ergocalciferol Capsules, a controlled substance?
Ergocalciferol Capsules, is not classified as a controlled substance by the DEA.
What is the generic name for Ergocalciferol Capsules,?
The generic name for Ergocalciferol Capsules, is Ergocalciferol Capsules,. There are 3 other brand versions of Ergocalciferol Capsules,.
What is the NDC code for Ergocalciferol Capsules, 1.25 mg/1?
The NDC (National Drug Code) for Ergocalciferol Capsules, 1.25 mg/1 is 68788-4042, listed by Preferred Pharmaceuticals Inc..